Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2017 | Pages:
50 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Pipeline Review, H2 2017 Summary According to the recently published report 'Leptin Receptor - Pipeline Review, H2 2017'; Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) pipeline Target constitutes close to 8 molecules. Out of which approximately 8 molecules are developed by Companies. Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Leptin receptor or LEP-R is a protein encoded by the LEPR gene. It acts as a receptor for hormone LEP/leptin. Upon binding it mediates LEP central and peripheral effects through the activation of different signaling pathways such as JAK2/STAT3 and MAPK cascade. LEP acts as an appetite-regulating factor that induces a decrease in food intake and an increase in energy consumption by inducing anorexinogenic factors and suppressing orexigenic neuropeptides also regulates bone mass and secretion of hypothalamo-pituitary-adrenal hormones. In the periphery increases basal metabolism, influences reproductive function, regulates pancreatic beta-cell function and insulin secretion, is pro-angiogenic and affects innate and adaptive immunity. The report 'Leptin Receptor - Pipeline Review, H2 2017' outlays comprehensive information on the Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities. It also reviews key players involved in Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration and Preclinical stages are 1 and 7 respectively. Report covers products from therapy areas Metabolic Disorders, Central Nervous System and Oncology which include indications Obesity, Alzheimer's Disease, Lipodystrophy, Type 2 Diabetes, Acquired Generalized Lipodystrophy (Lawrence Syndrome), Acquired Partial Lipodystrophy (Barraquer-Simons Syndrome), Breast Cancer, Congenital Generalized Lipodystrophy (Berardinelli-Seip Syndrome) and Type 1 Diabetes (Juvenile Diabetes). Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - The report reviews Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics and enlists all their major and minor projects - The report assesses Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Overview Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Companies Involved in Therapeutics Development ConSynance Therapeutics Inc Jyant Technologies Inc NeuroNano Pharma Inc Neurotez Inc Novelion Therapeutics Inc XL-protein GmbH Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Drug Profiles CV-08 - Drug Profile Product Description Mechanism Of Action R&D Progress memtin - Drug Profile Product Description Mechanism Of Action R&D Progress metreleptin - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibody Conjugate to Agonize Leptin Receptor for Metabolic Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress Peptide to Antagonize Leptin Receptor II for Triple Negative Breast Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant Protein to Agonize Leptin Receptor for Obesity - Drug Profile Product Description Mechanism Of Action R&D Progress Synthetic Peptide to Agonize Leptin Receptor for Metabolic Disorders and Alzheimer's Disease - Drug Profile Product Description Mechanism Of Action R&D Progress XL-100 - Drug Profile Product Description Mechanism Of Action R&D Progress Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Dormant Products Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Discontinued Products Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Product Development Milestones Featured News & Press Releases Jun 12, 2017: Novelion Therapeutics Announces Presentation of Metreleptin Data at American Diabetes Association May 05, 2017: Novelion Therapeutics Announces Presentation of Metreleptin Data at American Association of Clinical Endocrinology Apr 04, 2017: Metreleptin and Lipodystrophy Data Presented at the Annual Meeting of the Endocrine Society Mar 30, 2017: Novelion Therapeutics Subsidiary Announces New Data to be Presented at the Annual Meeting of the Endocrine Society Jan 23, 2017: Novelion Therapeutics Announces Acceptance of Marketing Authorization Application for Metreleptin by European Medicines Agency Dec 22, 2016: Novelion Therapeutics Subsidiary Files for European Approval for Metreleptin as a treatment for Generalized Lipodystrophy and a Subset of Patients with Partial Lipodystrophy Feb 25, 2014: FDA approves Myalept to treat rare metabolic disease Dec 12, 2013: FDA Advisory Committee votes on investigational medicine metreleptin Jun 04, 2013: Bristol-Myers Squibb And AstraZeneca Receive FDA Priority Review Designation For Metreleptin May 06, 2013: Bristol-Myers Squibb And AstraZeneca Announce Positive Results From Sub-Group Analysis Of Metreleptin In Pediatric Patients With Lipodystrophy Aug 01, 2012: Shionogi Files New Drug Application For Recombinant Human Leptin For Lipodystrophy Jul 27, 2012: Neurotez Receives US Patent 8,227,408 Covering Leptin Therapy For Alzheimer's Disease Jun 25, 2012: New Clinical Data Analyses Show Amylin Pharma's Metreleptin Reduced Blood Glucose And Triglyceride Levels In Patients With Rare Forms Of Lipodystrophy Apr 03, 2012: Amylin Completes Biologics License Application For Metreleptin To Treat Diabetes And/Or Hypertriglyceridemia In Patients With Rare Forms Of Lipodystrophy Jun 04, 2011: Amylin's Study Results Show Treatment With Metreleptin Improves Diabetes And Lipid Control In Patients With Partial Lipodystrophy Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H2 2017 Number of Products under Development by Therapy Areas, H2 2017 Number of Products under Development by Indication, H2 2017 Number of Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 Number of Products by Stage and Mechanism of Actions, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Pipeline by ConSynance Therapeutics Inc, H2 2017 Pipeline by Jyant Technologies Inc, H2 2017 Pipeline by NeuroNano Pharma Inc, H2 2017 Pipeline by Neurotez Inc, H2 2017 Pipeline by Novelion Therapeutics Inc, H2 2017 Pipeline by XL-protein GmbH, H2 2017 Dormant Projects, H2 2017 Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
